| Click for the Finfacts Ireland Portal Homepage |

Finfacts Business News Centre

 Irish Economy
 EU Economy
 US Economy
 UK Economy
 Global Economy
 Asia Economy

Finfacts changes from 2015


How to use our RSS feed

Follow Finfacts on Twitter

Web Finfacts

See Search Box lower down this column for searches of Finfacts news pages. Where there may be the odd special character missing from an older page, it's a problem that developed when Interactive Tools upgraded to a new content management system.


Finfacts is Ireland's leading business information site and you are in its business news section.


Finfacts Homepage

Irish Share Prices

Euribor Daily Rates

Global Cost of Living

Irish Tax - Income/Corporate




Content Management by interactivetools.com.

News : Innovation Last Updated: Jan 13, 2015 - 12:10 PM

Elan: Most valuable Irish firm becomes cash/ royalty shell
By Michael Hennigan, Finfacts founder and editor
May 14, 2013 - 5:48 AM

Email this article
 Printer friendly page

Elan's share price peaked in New York in mid-2001 at $61. It closed at $11.61 on Monday, May 13, 2013.

Elan, the commonly referred to 'Irish drugs firm,' that was the most valuable Irish public company in 2001 has joined surviving banks as a shadow of its former self. It has effectively shrunk itself to a royalty/ cash investment shell but it maintains its corporate headquarters in Ireland to avail of the favourable tax benefits.

Elan had over 1,700 staff worldwide in December 2006 with about 600 based in Ireland. In 2012, it had 245 employees worldwide of whom it said 86 (2011: 226 employees) were engaged in research and development activities  and the remainder were involved in other corporate functions. In 2013, staff levels are down to 90-100 with most of them based at the headquarters in Dublin.

Elan in an effort to head off a $6.6bn takeover bid from Royalty Pharma, a US royalty/cash shell like itself, announced on Monday a $1bn investment in Theravance, a California-based respiratory drug company.

GlaxoSmithKline, owns 27% of Theravance and according to Lex of the FT, respiratory drugs accounted for 40% of GSK’s pharmaceuticals sales in 2012. Elan has purchased of 21% of Theravance’s share – up to a fifth – of future sales and Elan in effect says [pdf] its Irish tax advantages will give it an edge (it also has large accumulated tax losses) but the drugs will have to be blockbusters as it has in effect bought a 2 to 3% share of the royalties.

Alkermes, a US pharmaceutical company, acquired Elan's Irish manufacturing plant in Athlone in 2011. Under the terms of the business combination agreement, Elan received $500m in cash and 31.9m ordinary shares of Alkermes plc, representing approximately 25% of Alkermes plc. The transaction enabled Elan to cut its debt by 51%. Alkermes this year announced 130 jobs cuts.

Elan has been involved in a number of other spinoffs in recent years and this year it sold its stake in Tysabri (nataluzimab), the multiple sclerosis blockbuster, to Biogen Idec of the United States, its partner, for $3.25bn. For the first twelve months after the deal closes, the deal will amount to 12% of annual Tysabri sales. After that it will leap to 18% of sales up to $2bn and 25% of sales over $2bn. (If Tysabri were to generate $2.5bn in sales, Elan would receive $485m.) Last year, Tysabri sales were at $1.6bn, up 8% from 2011.

The Neotope unit was spinoff in 2012 after the failure of its key Alzheimer’s treatment. It had evolved from Athena Neurosciences, the South San Francisco biotech business that Elan acquired in 1996 - - this firm was responsible for the discovery and development of Tysabri.

Elan expects its shell operation to be profitable in 2013 and it has more than $4bn in accumulated losses.

Elan was founded in Ireland in 1969 as a drug-delivery business, by American chemist Don Panoz, to facilitate the development of the technology behind the nicotine patch. It became a public limited company in January 1984.

By mid 2001, with the prospect of blockbuster drugs for Crohn's disease and multiple sclerosis (MS), Elan's share price rose to $61 in New York, making the company Ireland's most valuable firm. In December 2001, Elan's market capitalisation in Dublin accounted for about 20% of the total market value.

In 2002, Elan had a near-death experience in the aftermath of questions about its accounting policies and the adverse results from drug trials.

On February 8, 2002, Elan had acknowledged that the US Securities and Exchange Commission (SEC) was investigating how the then world's 20th-largest drug company accounted for its research-and-development expenditures.

The announcement followed a January 30, 2002, Wall Street Journal report that disclosed the existence of 55 joint ventures that Elan had structured to simultaneously shift R&D costs off its books and bring in revenue before any drugs are developed.

Elan admitted the accounting fraud by acknowledging that its previous year's profits would've been more than 40% lower and its debts $1bn higher than reported, if it had consolidated two of its 55 R&D vehicles onto its financial statements. By July 2002, Elan's shares had plummeted nearly 95% in six months.

Tysabri, the MS drug, was launched in 2004 and many analysts had expected the drug to generate peak annual sales of as much as $4bn, but it was promptly taken off the market in March 2005 after three patients developed a potentially fatal brain infection called progressive multifocal leukoencephalopathy. However, following an extensive safety review on both sides of the Atlantic, Tysabri was relaunched in July 2006 for the treatment of MS, with certain restrictions.

In 2010, Elan recorded operating profits, before other charges and gains, for the first time since 2001.

Today, Elan's shares are mainly held by Americans and it contributes little to the Irish economy. It is effectively Irish in name only. In 2007, the Elan chairman considered moving the headquarters to the US.

The current shareholders are getting bonanzas but it's thin gruel for the investments by Paddy Muggins, the Irish taxpayer.

It is a lesson for Irish policy makers and their delusional knowledge economy strategy. This inconvenient fact of course will remain inconvenient.

Meanwhile, Ireland is as dependent on foreign firms today as it was in 1990. However, FDI has peaked.

Lex video

Check out our subscription service, Finfacts Premium , at a low annual charge of €25 - - if you are a regular user of Finfacts, 50 euro cent a week is hardly a huge ask to support the service.

Related Articles

© Copyright 2015 by Finfacts.ie

Top of Page

Latest Headlines
Digital Taylorism: Amazon's chief rejects depiction of "soulless, dystopian workplace"
Most surviving startups do not grow; Tiny number powers jobs engine
Despite euro dip China & US remain most competitive manufacturing nations
Business startup rates up in most OECD countries led by Australia and UK
NASA's Kepler mission has confirmed the first near-Earth-size planet
Energy subsidies at 6.5% of global GDP; Commodity prices to remain weak
US startups rely on personal savings, debt; Venture capital funds less than 1%
Europe produces 13 $1bn+ "unicorn" startups in one year; London is Europe's digital capital
Irish-based firms raised €120m in VC funding in Q1 2015; Some top recipients Irish for tax purposes
Ireland: Fourth highest 25-34 year old ratio of third-level graduates in developed world: So what?
Business dynamism/ employer firm startups in US secular decline
Innovation Union Scoreboard 2015: Sweden, Denmark, Finland and Germany are on top
Education systems failing to provide students with skills for success in 21st century
US, Switzerland, Denmark, Sweden, Finland have best higher education systems
Handbook of Service Innovation: Ireland moving up the value chain?
Switzerland revives silk industry that thrived for two centuries
Sales of Irish tech firms create 300 millionaires in 15 years and no scaleups
Apple warns of 'material' tax payments from EU's Irish tax investigation
Apple earnings surge 33% on higher price and iPhone sales jump in China
Big Pharma's internationalisation of R&D to China
The dangers of romanticising entrepreneurs despite key role
UK and Irish business R&D heavily reliant on foreign-owned firms
Silicon Valley and the development of the silicon microchip - Part 2
Ireland: Innovation with or without R&D/ scientific breakthroughs
UK government most open/ transparent in world; Ireland & Greece lowest ranking in Europe
10 questions about Switzerland's Solar Impulse aircraft – answered
Silicon Valley loses its silicon; Typical household income stagnates - Part 1
21st century skills are 18 century skills + a computer
Growing ICT sector in Europe accounts for 5% of employment
Should Ireland copy Singapore's scientific research investment plan?
Startups vs Scaleups: 4% of UK startups have 10+ employees 10 years later
Irish patent filings at European Patent Office fell in 2014
Facebook's maze of privacy settings maybe in breach of European law
Apple to invest €1.7bn in Irish and Danish data centres
Silicon Valley insider warns of dodgy $1bn valuations of private companies
Israel's Startup Nation not a jobs engine; Nor is Irish high tech
Established industries often beat new technology investment returns
Ireland: Noonan said EU to drop Apple tax case; Now expects court case
Irish R&D Tax Credit: No evidence of rising business innovation; Facts don't matter
Apple reports biggest profit of a public company in history